CIC
PLRX icon

Cornercap Investment Counsel’s Pliant Therapeutics PLRX Stock Holding History

Cornercap Investment Counsel’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,280
Closed -$194K – 608
2022
Q2 		$194K Buy
+24,280
New +$155K 0.03% 490

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cornercap Investment Counsel's PLRX Position: Q3 2022 in Review

Cornercap Investment Counsel sold out of Pliant Therapeutics (PLRX) in Q3 2022, closing a stake of 24,280 shares — an estimated $194K sold.

Cornercap Investment Counsel first reported a position in PLRX in Q2 2022 and held it in 1 quarter. The position peaked at $194K in Q2 2022. 110 funds tracked by Wall St. Rank hold PLRX as of Q3 2022.

  • Cornercap Investment Counsel reported no remaining Pliant Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 24,280 Pliant Therapeutics shares in Q3 2022, an estimated $194K.
  • Cornercap Investment Counsel first reported a position in Pliant Therapeutics in Q2 2022 and held it in 1 quarter.
  • Cornercap Investment Counsel's Pliant Therapeutics position peaked at $194K in Q2 2022.
  • 110 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2022.

Based on Cornercap Investment Counsel's 13F filing for Q3 2022, filed 14 Nov 2022.